These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 28785052)
1. The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards. Park SY; Love TMT; Reynell L; Yu C; Kang TM; Anastos K; DeHovitz J; Liu C; Kober KM; Cohen M; Mack WJ; Lee HY Sci Rep; 2017 Aug; 7(1):7480. PubMed ID: 28785052 [TBL] [Abstract][Full Text] [Related]
2. Precision detection of recent HIV infections using high-throughput genomic incidence assay. Faraci G; Park SY; Love TMT; Dubé MP; Lee HY Microbiol Spectr; 2023 Sep; 11(5):e0228523. PubMed ID: 37712639 [TBL] [Abstract][Full Text] [Related]
3. Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations. Kirkpatrick AR; Patel EU; Celum CL; Moore RD; Blankson JN; Mehta SH; Kirk GD; Margolick JB; Quinn TC; Eshleman SH; Laeyendecker O AIDS Res Hum Retroviruses; 2016 Aug; 32(8):756-62. PubMed ID: 26988426 [TBL] [Abstract][Full Text] [Related]
4. Performance of Bio-Rad and Limiting Antigen Avidity Assays in Detecting Recent HIV Infections Using the Quebec Primary HIV-1 Infection Cohort. Serhir B; Hamel D; Doualla-Bell F; Routy JP; Beaulac SN; Legault M; Fauvel M; Tremblay C; PLoS One; 2016; 11(5):e0156023. PubMed ID: 27224023 [TBL] [Abstract][Full Text] [Related]
5. Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance. Sempa JB; Welte A; Busch MP; Hall J; Hampton D; Facente SN; Keating SM; Marson K; Parkin N; Pilcher CD; Murphy G; Grebe E; PLoS One; 2019; 14(7):e0220345. PubMed ID: 31348809 [TBL] [Abstract][Full Text] [Related]
6. Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting "Recent" HIV Infection and Calculating Population Incidence. Keating SM; Kassanjee R; Lebedeva M; Facente SN; MacArthur JC; Grebe E; Murphy G; Welte A; Martin JN; Little S; Price MA; Kallas EG; Busch MP; Pilcher CD J Acquir Immune Defic Syndr; 2016 Dec; 73(5):581-588. PubMed ID: 27509247 [TBL] [Abstract][Full Text] [Related]
7. Developing high-throughput HIV incidence assay with pyrosequencing platform. Park SY; Goeken N; Lee HJ; Bolan R; Dubé MP; Lee HY J Virol; 2014 Mar; 88(5):2977-90. PubMed ID: 24371062 [TBL] [Abstract][Full Text] [Related]
8. HIITE: HIV-1 incidence and infection time estimator. Park SY; Love TMT; Kapoor S; Lee HY Bioinformatics; 2018 Jun; 34(12):2046-2052. PubMed ID: 29438560 [TBL] [Abstract][Full Text] [Related]
9. Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms. Grebe E; Welte A; Hall J; Keating SM; Facente SN; Marson K; Martin JN; Little SJ; Price MA; Kallas EG; Busch MP; Pilcher CD; Murphy G J Acquir Immune Defic Syndr; 2017 Dec; 76(5):547-555. PubMed ID: 28914669 [TBL] [Abstract][Full Text] [Related]
10. Microdrop Human Immunodeficiency Virus Sequencing for Incidence and Drug Resistance Surveillance. Park SY; Faraci G; Murphy G; Pilcher C; Busch MP; Lee HY J Infect Dis; 2021 Sep; 224(6):1048-1059. PubMed ID: 33517458 [TBL] [Abstract][Full Text] [Related]
12. The impact of non-disclosure of HIV status and antiretroviral therapy on HIV recency testing and incidence algorithms. van den Berg K; Murphy EL; Maartens G; Louw VJ; Grebe E Vox Sang; 2024 Jun; 119(6):581-589. PubMed ID: 38622931 [TBL] [Abstract][Full Text] [Related]
13. Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana. Moyo S; Vandormael A; Wilkinson E; Engelbrecht S; Gaseitsiwe S; Kotokwe KP; Musonda R; Tanser F; Essex M; Novitsky V; de Oliveira T PLoS One; 2016; 11(8):e0160649. PubMed ID: 27552218 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Abbott ARCHITECT HIV Ag/Ab combo assay for determining recent HIV-1 infection. Curtis KA; Rudolph DL; Pan Y; Delaney K; Anastos K; DeHovitz J; Kassaye SG; Hanson CV; French AL; Golub E; Adimora AA; Ofotokun I; Bolivar H; Kempf MC; Peters PJ; Switzer WM PLoS One; 2021; 16(7):e0242641. PubMed ID: 34197451 [TBL] [Abstract][Full Text] [Related]
15. Short Communication: Low False Recent Rate of Limiting Antigen-Avidity Assay Combined with HIV-1 RNA Data in Botswana. Moyo S; Kotokwe KP; Mohammed T; Boleo C; Mupfumi L; Chishala S; Tsalaile L; Bussmann H; Gaseitsiwe S; Musonda R; Makhema J; Baum M; Marlink R; Engelbrecht S; Essex M; Novitsky V AIDS Res Hum Retroviruses; 2017 Jan; 33(1):17-18. PubMed ID: 27481530 [TBL] [Abstract][Full Text] [Related]
16. Validation of the Limiting Antigen Avidity Assay to Estimate Level and Trends in HIV Incidence in an A/D Epidemic in Rakai, Uganda. Laeyendecker O; Gray RH; Grabowski MK; Reynolds SJ; Ndyanabo A; Ssekasanvu J; Fernandez RE; Wawer MJ; Serwadda D; Quinn TC AIDS Res Hum Retroviruses; 2019 Apr; 35(4):364-367. PubMed ID: 30560723 [TBL] [Abstract][Full Text] [Related]
18. A Generalized Entropy Measure of Within-Host Viral Diversity for Identifying Recent HIV-1 Infections. Wu JW; Patterson-Lomba O; Novitsky V; Pagano M Medicine (Baltimore); 2015 Oct; 94(42):e1865. PubMed ID: 26496342 [TBL] [Abstract][Full Text] [Related]
19. Designing a genome-based HIV incidence assay with high sensitivity and specificity. Park SY; Love TM; Nelson J; Thurston SW; Perelson AS; Lee HY AIDS; 2011 Oct; 25(16):F13-9. PubMed ID: 21716075 [TBL] [Abstract][Full Text] [Related]
20. Performance characteristics of an antibody-based multiplex kit for determining recent HIV-1 infection. Curtis KA; Hanson DL; Price KA; Owen SM PLoS One; 2017; 12(5):e0176593. PubMed ID: 28472089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]